Found 18 clinical trials
Analysis of Capillary Retinal and Papillary Vascularization in Patients With Amyotrophic Lateral Sclerosis - CAPISLA
patients are affected in France. The only therapeutic treatment available to date in France is riluzole, which slows the progression of the disease. Amyotrophic Lateral Sclerosis is the first degenerative
- 0 views
- 14 Oct, 2021
- 1 location
The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.
Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is 3 years. Apart from Riluzole, there is no
- 12 views
- 20 Jun, 2021
- 9 locations
A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study
Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The mean survival from the time of diagnosis is 2.5 years. Apart from Riluzole, there is no
- 0 views
- 03 Nov, 2021
- 17 locations
iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study
This is a phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of bosutinib to determine the maximum tolerated dose(MTD) and a recommended phase 2 dose (RP2D) of bosutinib for treatment of ALS patients. Also, efficacy will be evaluated exploratory.
- 0 views
- 19 Feb, 2021
- 4 locations
Arbaclofen in Children and Adolescents With ASD
AIMS-2-CT-01 is a randomized, double-blind, placebo controlled, study to explore the efficacy, safety and tolerability of Arbaclofen administered to children and adolescents (ages 5-17) for the treatment of social adaptive function in participants with ASD. The effects of Arbaclofen on social function in children and adolescents with ASD will be …
- 15 views
- 04 Oct, 2021
- 7 locations
Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients
Amyotrophic lateral sclerosis (ALS) is a disease of an inflammatory nature, which causes progressive muscle weakness associated with cognitive and behavioural disorders. Pathogenically, it is characterised by loss of oxidative control, excitotoxicity due to excess glutamate and intestinal dysbiosis. In the absence of curative treatment, the aim of the study …
- 13 views
- 26 Dec, 2021
- 1 location
COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness involving limb, bulbar, and respiratory muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed with amyotrophic lateral sclerosis (ALS). This is especially important as respiratory compromise is common in ALS patients and …
- 0 views
- 26 Jan, 2021
- 1 location
Amyotrophic Lateral Sclerosis and the Innate Immune System
Amyotrophic Lateral Sclerosis (ALS) is an aggressive, deadly disease. ALS leads to destruction of the neural pathways which control the conscious movements of the muscles. This destruction leads to muscular dystrophy with increasing difficulties in moving, breathing, swallowing, and speaking. In the last phase of an ALS patient's life it …
- 82 views
- 21 Jan, 2021
- 7 locations
- 1
- 2